ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
暂无分享,去创建一个
Marie Perier-Muzet | Maxime Battistella | Arnaud de la Fouchardière | L. Thomas | C. Bertolotto | R. Ballotti | C. Lebbé | A. Puisieux | S. Dalle | R. Pommier | E. Thomas | S. Ansieau | J. Caramel | M. Battistella | S. Mourah | A. Boespflug | G. Richard | Luc Thomas | Alain Puisieux | Stéphane Dalle | A. de la Fouchardière | G. Tondeur | L. Depaepe | M. Perier-Muzet | Samia Mourah | Céleste Lebbé | Corine Bertolotto | Robert Ballotti | Julie Caramel | Stéphane Ansieau | Emilie Thomas | Geoffrey Richard | Marie-Ambre Monet | Maud Ligier | Amélie Boespflug | Roxane M Pommier | Lauriane Depaepe | Romain Barnault | Garance Tondeur | Maud Ligier | Marie Monet | R. Barnault | Roxane M. Pommier
[1] Annette Meeson,et al. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. , 2014, Cancer treatment reviews.
[2] T. Keck,et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat , 2015, EMBO molecular medicine.
[3] Charis Eng,et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. , 2008, Cancer research.
[4] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[5] Irving L. Weissman,et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271 , 2011, Nature.
[6] D. Dean,et al. Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis , 2014, Nature Communications.
[7] S. Morrison,et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.
[8] A. Dhillon,et al. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL , 2012, Oncogene.
[9] T. Tan,et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients , 2014, EMBO molecular medicine.
[10] Irving L. Weissman,et al. Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.
[11] Robert A. Weinberg,et al. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity , 2013, Cell.
[12] Tatyana Chernova,et al. Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. , 2007, Molecular biology of the cell.
[13] Mohamed H. Sayegh,et al. Identification of cells initiating human melanomas , 2008, Nature.
[14] J. Dou,et al. Effect of downregulation of ZEB1 on vimentin expression, tumour migration and tumourigenicity of melanoma B16F10 cells and CSCs , 2014, Cell biology international.
[15] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.
[16] A. Puisieux,et al. Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.
[17] Frank McCormick,et al. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond , 2014, Nature Reviews Cancer.
[18] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[19] H. Moch,et al. Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth. , 2011, Cancer research.
[20] Steven J. M. Jones,et al. Genomic Classification of Cutaneous Melanoma , 2015, Cell.
[21] R. Weinberg,et al. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.
[22] J. Larkin,et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. , 2015, Cancer cell.
[23] R. Moon,et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. , 2014, The Journal of clinical investigation.
[24] W. Huber,et al. which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .
[25] N. Rosen,et al. Tumor adaptation and resistance to RAF inhibitors , 2013, Nature Medicine.
[26] J. Lachuer,et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.
[27] P. Bahadoran,et al. CD271 is an imperfect marker for melanoma initiating cells , 2014, Oncotarget.
[28] T. Graeber,et al. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma , 2014, Nature Communications.
[29] R. Huang,et al. Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.
[30] C. Wellbrock,et al. Microphthalmia‐associated transcription factor in melanoma development and MAP‐kinase pathway targeted therapy , 2015, Pigment cell & melanoma research.
[31] S. Nelson,et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation , 2010, Nature.
[32] H. Lehrach,et al. The Nerve Growth Factor Receptor CD271 Is Crucial to Maintain Tumorigenicity and Stem-Like Properties of Melanoma Cells , 2014, PloS one.
[33] G. Berx,et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression , 2014, Cell Death and Differentiation.
[34] N. Hayward,et al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma , 2014, Nature Communications.
[35] J. Mesirov,et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. , 2014, Cancer discovery.
[36] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[37] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[38] S. Rorive,et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. , 2015, Cell stem cell.
[39] K. Hoek,et al. Cancer stem cells versus phenotype‐switching in melanoma , 2010, Pigment cell & melanoma research.
[40] J. Lachuer,et al. EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice , 2012, PLoS genetics.
[41] Tuan Zea Tan,et al. Epithelial–mesenchymal status renders differential responses to cisplatin in ovarian cancer , 2014, Oncogene.
[42] S. Morrison,et al. Efficient tumor formation by single human melanoma cells , 2008, Nature.
[43] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[44] A. Roesch. Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma , 2014, Oncogene.
[45] Li Ma,et al. ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance , 2015, Cell cycle.
[46] J. Pringle,et al. Plasticity of melanoma and EMT-TF reprogramming , 2013, Oncotarget.
[47] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[48] W. Woodward,et al. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1 , 2014, Nature Cell Biology.
[49] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[50] Rajiv Narayan,et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition , 2013, Nature.
[51] A. McKenna,et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. , 2014, Cancer discovery.
[52] D. Kusewitt,et al. Slug expression during melanoma progression. , 2012, The American journal of pathology.
[53] A. Puisieux,et al. Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition , 2008, PloS one.
[54] S. Aerts,et al. Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state , 2015, Nature Communications.
[55] J. Settleman,et al. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.
[56] Antoni Ribas,et al. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance , 2015, Cell.
[57] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.